trending Market Intelligence /marketintelligence/en/news-insights/trending/71xBOnkLB6AL88ag433Efg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Lonza secures long-term agreement to manufacture kidney drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lonza secures long-term agreement to manufacture kidney drug

Lonza Group Ltd. nabbed a contract to manufacture Voclosporin on Aurinia Pharmaceuticals Inc.'s behalf.

Lonza Group will supply the patent-protected investigational drug for phase 3 clinical trial to determine whether it can be used to treat lupus nephritis, an inflammation of the kidneys.

The agreement also gives Lonza exclusivity to supply the drug for up to 20 years.